Ciclosilicato de Sodio y Zirconio: Análisis de la Evidencia

Instagram: ⁠@dr.gilbertogarciabernal⁠Infografías en X: ⁠@GilbertoG_MDSodium zirconium cyclosilicate for renin–angiotensin–aldosterone system inhibitor therapy optimization: A systematic review and meta-analysis with meta-regression (Nefrologia, 2026)Este metaanálisis confirma que el ciclosilicato de sodio y zirconio (CSZ) facilita el mantenimiento y la optimización de dosis de fármacos cardioprotectores. Se asocia con un riesgo un 44% menor de discontinuar los iSRAA y establece una relación directa entre el descenso de potasio y la persistencia del tratamiento. The randomized DIALIZE-Outcomes trial (Kidney Int, 2025)Renin‑Angiotensin‑Aldosterone System Inhibitor Dosing After Initiation of Outpatient Sodium Zirconium Cyclosilicate Therapy: The GALVANIZE RAASi Real‑World Evidence Study (Adv Ther, 2025)Sodium zirconium cyclosilicate versus sodium polystyrene sulfonate for treatment of hyperkalemia in hemodialysis patients: a randomized clinical trial (BMC Nephrol, 2025)Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients With Heart Failure (J Am Coll Cardiol, 2025)The Association of Heart Failure and Edema Events between Patients Initiating Sodium Zirconium Cyclosilicate or Patiromer (Kidney360, 2024)Sodium Zirconium Cyclosilicate in CKD, Hyperkalemia, and Metabolic Acidosis: NEUTRALIZE Randomized Study (Kidney360, 2024)] Maintained renin–angiotensin–aldosterone system inhibitor therapy with sodium zirconium cyclosilicate following a hyperkalaemia episode: a multicountry cohort study (Clin Kidney J, 2024)Impact of Sodium Zirconium Cyclosilicate Plus Renin–Angiotensin–Aldosterone System Inhibitor Therapy on Short-Term Medical Costs in Hyperkalemia: OPTIMIZE II Real-World Study (Adv Ther, 2023)DIALIZE China: A Phase IIIb, Randomized, Placebo-Controlled Study to Reduce Predialysis Hyperkalemia With Sodium Zirconium Cyclosilicate in Chinese Patients (Clin Ther, 2023)Potassium reduction with sodium zirconium cyclosilicate in patients with heart failure (ESC Heart Fail, 2023)Patiromer and Sodium Zirconium Cyclosilicate in Treatment of Hyperkalemia: A Systematic Review and Meta-Analysis (Curr Ther Res Clin Exp, 2021)Effects and Safety of a Novel Oral Potassium-Lowering Drug-Sodium Zirconium Cyclosilicate for the Treatment of Hyperkalemia: a Systematic Review and Meta-Analysis (Cardiovasc Drugs Ther, 2021)Emergency Potassium Normalization Treatment Including Sodium Zirconium Cyclosilicate: A Phase II, Randomized, Double-blind, Placebo-controlled Study (ENERGIZE) (Acad Emerg Med, 2020)Efficacy and safety of sodium zirconium cyclosilicate for hyperkalaemia: the randomized, placebo-controlled HARMONIZE-Global study (ESC Heart Fail, 2020)Efficacy and safety of sodium zirconium cyclosilicate in patients with baseline serum potassium level ≥ 5.5 mmol/L: pooled analysis from two phase 3 trials (BMC Nephrol, 2019)Efficacy and Safety of Sodium Zirconium Cyclosilicate for Treatment of Hyperkalemia: An 11-Month Open-Label Extension of HARMONIZE (Am J Nephrol, 2019)A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study of Sodium Zirconium Cyclosilicate for Reducing the Incidence of Predialysis Hyperkalemia (J Am Soc Nephrol, 2019)Sodium Zirconium Cyclosilicate among Individuals with Hyperkalemia: A 12-Month Phase 3 Study (Clin J Am Soc Nephrol, 2019)Sodium Zirconium Cyclosilicate in Hyperkalemia (N Engl J Med, 2015)Effect of Sodium Zirconium Cyclosilicate on Potassium Lowering for 28 Days Among Outpatients With Hyperkalemia: The HARMONIZE Randomized Clinical Trial (JAMA, 2014)